134 F. Supp. 3d 1358
M.D. Fla.2015Background
- Rebecca Small used Enbrel (a TNF antagonist) for rheumatoid arthritis from 2002 until emergency hospitalization for perforated bowel from diverticulitis in Aug. 2008; she resumed Enbrel in Feb. 2009 and suffered further complications.
- Plaintiffs sued Amgen, Wyeth (acquired by Pfizer), and Pfizer alleging design defect (Count I), failure to warn (Count II), breach of express warranty (Count III), negligence (Count IV), and loss of consortium (Count V).
- Defendants distributed FDA‑approved package inserts and medication guides that warned of serious infections associated with Enbrel; plaintiffs claim defendants failed to warn about asymptomatic infections and failed to provide guidance on resuming therapy after infection.
- The core dispositive issue on summary judgment was whether Florida’s learned intermediary doctrine bars plaintiffs’ failure‑to‑warn claims because the prescribing physician (Dr. Kowal) would have prescribed Enbrel even if the insert warned of asymptomatic infections.
- The district court found Dr. Kowal had independent knowledge of Enbrel’s infection risks (including asymptomatic infections and intestinal perforation) and testified she would have prescribed or resumed Enbrel regardless of additional warnings; summary judgment was granted on failure‑to‑warn and negligent failure‑to‑warn claims but denied as to design, manufacturing, and express‑warranty claims.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Whether medication‑guide regulations (21 C.F.R. § 208) abrogate or displace Florida’s learned intermediary doctrine | Medication guides create a federal duty to warn patients, so learned intermediary should not apply or is preempted | Learned intermediary remains applicable under Florida law; medication‑guide regs do not alter state tort duties or preempt state law | Court: Learned intermediary applies; medication‑guide regs do not abrogate or preempt it |
| Whether learned intermediary doctrine is preempted (field or conflict preemption) | Regulations occupy the field or conflict with state law by imposing a patient‑directed duty | Wyeth v. Levine and related authority show Congress/FDA did not intend to preempt state tort law; no conflict exists | Court: No field or conflict preemption; learned intermediary survives |
| Whether defendants’ failure to warn (of asymptomatic infections and resumption guidance) proximately caused Ms. Small’s injuries | Absent warnings about asymptomatic infections and resumption guidance, physician would have acted differently and injury would have been avoided | Dr. Kowal knew the risks (including asymptomatic infections and GI perforation) and would have prescribed/resumed Enbrel regardless; sales rep statements irrelevant | Court: Dr. Kowal’s testimony defeats causation; summary judgment for defendants on failure‑to‑warn and negligent failure‑to‑warn claims |
| Whether design, manufacturing, and express‑warranty claims are barred by learned intermediary / comment k (unavoidably unsafe product) | Enbrel was defectively designed/manufactured and express warranties were breached | Defendants invoke comment k and learned intermediary to bar design liability, arguing benefits outweigh risks and proper warnings negate liability | Court: Denied summary judgment on design, manufacturing, and express warranty claims (insufficient evidence on safety as of distribution; discovery still open) |
Key Cases Cited
- Wyeth v. Levine, 555 U.S. 555 (state law failure‑to‑warn claims against drug manufacturers are not preempted by the FDCA)
- Buckner v. Allergan Pharms., Inc., 400 So.2d 820 (Fla. 5th DCA) (manufacturer’s duty to warn runs to prescribing physician under learned intermediary doctrine)
- Felix v. Hoffmann‑La Roche, Inc., 540 So.2d 102 (Fla. 1989) (discussing adequacy of warnings and learned intermediary in Florida)
- Guarino v. Wyeth, LLC, 719 F.3d 1245 (11th Cir.) (prescribing physician as learned intermediary weighing benefits and risks)
- Mason v. Hoffmann‑La Roche, Inc., 27 So.3d 75 (Fla. 5th DCA) (proximate‑cause requirement for inadequate warning claims)